Skip to content
Triangle logo TriangleGet started
← Study library

NCT00060346 · REGISTRY CONDITION SEARCH

Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE2
Status at capture
TERMINATED
Registry last update
2023-06-29

RATIONALE: Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining rituximab with combination chemotherapy may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving rituximab together with combination chemotherapy works in treating patients with newly diagnosed Waldenstrom's macroglobulinemia.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Objective Response to Treatment

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
INCLUSION CRITERIA: * Diagnosis of Waldenstrom's macroglobulinemia confirmed by the presence of the following: * Bone marrow lymphoplasmacytosis with: \> 10% lymphoplasmacytic cells OR aggregates or sheets of one of the following: lymphocytes, plasma cells or lymphoplasmacytic cells on the bone marrow biopsy (measured within 4 weeks prior to registration) * Measurable disease defined as a quantitative immunoglobulin M (IgM) monoclonal protein of \> 1,000 mg/dL obtained within 4 weeks prior to registration * Cluster of differentiation 20 (CD20) positive stain of bone marrow or lymph node samples obtained \< 8 weeks prior to registration * Impaired bone marrow function due to infiltration by lymphoplasmacytic lymphoma, defined by 1 of the following: * Hemoglobin no greater than 11 g/dL * Serum viscosity level relative to water of at least 4.0 centipoise * Absolute neutrophil count at least 1,000/mm\^3 * Platelet count at least 75,000/mm\^3 * Bilirubin no greater than 3.0 mg/dL * Aspartate aminotransferase (AST) no greater than 3 times upper limit of normal * Creatinine no greater than 3.0 mg/dL * Age of 18 and over * ECOG (Eastern Cooperative Oncology Group) performance status 0-1 * Must be symptomatic with 1 of the following: * Clinically significant anemia (hemoglobin no greater than 11 g/dL) * Bulky lymphadenopathy * Symptoms attributable to hyperviscosity (e.g., nose bleeding, gingival bleeding, or retinal hemorrhage) * History of heart disease allowed only if 1 of the following is demonstrated by echocardiography, multigated acquisition scan (MUGA), exercise MUGA, or coronary catheterization: * Ejection fraction of at least 45% * Normal fractional shortening of the left ventricle * Must have been tested for hepatitis B surface antigen within 2 weeks of registration * Negative pregnancy test * Fertile patients must use effective contraception EXCLUSION CRITERIA: * Prior treatment for Waldenstrom's macroglobulinemia * Prior anti-CD20 therapy * Concurrent steroids exceeding 10 mg prednisone (or equivalent) per day * Prior irradiation if less than 4 weeks had elapsed prior to registration and the date of last treatment * Prior anthracyclines * Prior malignancy except curatively treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or other cancer curatively treated with surgery alone and from which patient has been disease free for at least 5 years * Active heart disease * Pregnant or nursing * Myocardial infarction within the past 3 months * Congestive heart failure * Symptomatic ventricular arrhythmia
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Rituximab 375 mg/m2 day 1 of a 21-day cycle, followed by: Cyclophosphamide 750 mg/m2 Doxorubicin 50 mg/m2 Vincristine 1.4 mg/m2 and Prednisone 100 mg/m2 daily
    intervention Names
    1. Biological: rituximab
    2. Drug: cyclophosphamide
    3. Drug: Doxorubicin
    4. Drug: Prednisone
    5. Drug: Vincristine
    label
    Rituximab + CHOP
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Rituximab + CHOP
    description
    Rituximab is given intravenously. The initial rate is 50 mg/hr for the 1st hour. If no toxicity, the rate may be escalated in 50 mg/hr increments at 30-minute intervals to a maximum of 400 mg/hr. If the first dose is well tolerated, the initial rate for subsequent dose is 100 mg/hr, increased in 100 mg/hr increments at 30-minute intervals, not to exceed 400 mg/hr. If the patient experiences fever and rigors, the antibody infusion is discontinued. The severity of the side effects should be evaluated. If the symptoms improve, the infusion is continued initially at half the previous rate. Following the antibody infusion, the intravenous line should be maintained for medications as needed. If there are no complications after one hour of observation, the intravenous line may be discontinued.
    name
    rituximab
    other Names
    1. IDEC-C2B8
    2. Chimeric anti-CD20 monoclonal antibody
    3. Rituxan
    4. NSC# 687451
    type
    BIOLOGICAL
  2. arm Group Labels
    1. Rituximab + CHOP
    description
    Cyclophosphamide will be given at a dosage of 750 mg/m² intravenously on day 1 of each cycle (1 cycle =21 days) for 6 cycles. Dose is based on surface area calculated based on actual body weight. The drug should be administered as a rapid IV infusion over 5 to 30 minutes.
    name
    cyclophosphamide
    other Names
    1. Cytoxan
    2. CTX
    3. CPM
    4. Neosar
    type
    DRUG
  3. arm Group Labels
    1. Rituximab + CHOP
    description
    Doxorubicin will be given intravenously at a dosage of 50 mg/m² on day 1 of each cycle for 6 cycles (1 cycle =21 days). Dose is based on surface area calculated based on actual body weight. Doxorubicin should be administered as a continuous infusion into tubing of a freely flowing intravenous line for 5 -15 minutes. Avoid extravasation.
    name
    Doxorubicin
    other Names
    1. Adriamycin
    2. Rubex
    3. Adriamycin RDF
    4. Adriamycin PFS
    5. hydroxydaunorubicin
    6. ADR
    type
    DRUG
  4. arm Group Labels
    1. Rituximab + CHOP
    description
    Prednisone will be administered at 100 mg/m² orally, days 1-5 of each cycle for 6 cycles (1 cycle =21 days). Dose is based on surface area calculated based on actual body weight.
    name
    Prednisone
    other Names
    1. Deltasone
    2. Orasone
    3. Medicortone
    4. Panasol-S
    5. Liqui-Pred
    type
    DRUG
  5. arm Group Labels
    1. Rituximab + CHOP
    description
    Vincristine will be administered 1.4 mg/m² intravenously (Maximum dose = 2.0 mg) on day 1 of each cycle for 6 cycles (1 cycle =21 days). Dose is based on surface area calculated based on actual body weight. Given as IV push over 1 minute, using extravasation precautions.
    name
    Vincristine
    other Names
    1. Vinsacar PFS
    2. vincristine sulfate
    3. VCR
    4. leucocristine
    5. LCR
    type
    DRUG
Study design
allocation
NA
intervention Model
SINGLE_GROUP
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
16
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Objective response assessed using standard myeloma response criteria. Objective response is defined as a \> 50% reduction in the quantitative IgM or M-Spike levels from baseline levels. Response must be documented by two measurements separated by at least 3 weeks.
    measure
    Objective Response to Treatment
    time Frame
    Every 3 months if patient is < 2 years from study entry, every 6 months if patient is 2-5 years from study entry, every 12 months if patient is 6-10 years from study entry
Full study description
brief Summary
RATIONALE: Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining rituximab with combination chemotherapy may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving rituximab together with combination chemotherapy works in treating patients with newly diagnosed Waldenstrom's macroglobulinemia.
detailed Description
OBJECTIVES: * Determine the response rate of patients with newly diagnosed Waldenstrom's macroglobulinemia treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone. * Determine the associated toxic effects of this regimen, specifically the frequency of febrile neutropenia, in these patients. * Determine the progression-free survival of patients treated with this regimen. * Correlate baseline cytogenetic features and gene expression profiles with response in patients treated with this regimen. OUTLINE: This is a pilot, multicenter study. Patients receive rituximab intravenously (IV) over approximately 4 hours, cyclophosphamide IV over 5-30 minutes, doxorubicin IV over 5-15 minutes, and vincristine IV over 1 minute on day 1. Patients also receive oral prednisone on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually for 5 years. ACTUAL ACCRUAL: A total of 16 patients were accrued for this study.
Source references
references
  1. citation
    Abonour R, Zhang LA, Rajkumar V, et al.: Phase II pilot study of rituximab + CHOP in patients with newly diagnosed Waldenstroms macroglobulinemia, an Eastren Cooperative Oncology Group trial (study E1A02). [Abstract] Blood 110 (11): A-3616, 2007.
    type
    RESULT
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-0b2c0d123720ee06c27a
      requested nct id
      NCT00060346
      primary nct id
      NCT00060346
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      payload sha256
      aae175e470b5c73f58e3d31d270c7c527aa012f199492a2bcfe8940a0059a773
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-0b2c0d123720ee06c27a
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT00060346
      occurrences
      1. context exact
        NCT00060346
        end
        11
        exact text
        NCT00060346
        start
        0
      offset unit
      unicode_code_points
      query cond
      Plasma Cell Neoplasms
      query disease state id
      ds-plasma-cell-neoplasms
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      source json pointer
      /studies/825/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      b4efabb3da6098b4559e91d707da37ab7267cd499fcdc76f351a0cd24ef6f3b5

    Preserved source evidence · Not medical advice